Methadone
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Methadone (D,L-methadone) |
| Overview | |
| FDA Approval | Yes (for pain management and replacement therapy for addiction) |
| Used for | Investigational use in glioblastoma treatment for its chemosensitizing effects |
| Clinical Trial Phase | Preclinical studies and a retrospective safety and tolerability study in glioma patients |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Nausea, constipation (obstipation); side effects commonly resolved after one month of therapy |
| OS without | Not specified in provided details |
| OS with | In a study with newly diagnosed GBM patients, progression-free survival at 6 months was 91% when methadone was added to the standard of care |
| PFS without | Not specified |
| PFS with | Significant in the context of preliminary findings from retrospective studies |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Methadone, primarily known for severe pain management and opioid replacement therapy, has demonstrated potential as a chemosensitizer in glioma cells through in vitro studies and mouse models. It exhibits this effect by inhibiting the activity of the DNA-repair enzyme MGMT and sensitizing cells to chemotherapy, along with blocking adenyl cyclase leading to decreased expression of anti-apoptotic proteins. Early clinical data suggest a positive impact on progression-free survival in glioblastoma patients when combined with standard treatments, although further research is needed to confirm efficacy and optimal dosing.
From Ben Williams Book: Not specified
Loading comments...
